Neuralstem to Raise $7.0 Million in Registered Direct

New Post Public Reply Private Reply Replies (0) Message Board

Sep 14, 2012 at 6:44 AM

Neuralstem to Raise $7.0 Million in Registered Direct Offering

ROCKVILLE, Md. , Sept. 13, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today announced the pricing of a registered direct offering of 7,000,000 shares of its common stock, offered at a price to the public of $1.00 per share. The gross proceeds to Neuralstem from this offering are expected to be $7.0 million , before deducting placement agent fees and other estimated offering expenses payable by Neuralstem. The offering is expected to close on or about September 19, 2012 , subject to customary closing conditions.

Aegis Capital Corp. is acting as sole placement agent for this offering.

The offering is being made pursuant to a shelf registration statement that Neuralstem filed with the Securities and Exchange Commission ("SEC") and is effective. A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and a final prospectus supplement and accompanying base prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY , 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com . Electronic copies of the final prospectus supplement and accompanying base prospectus will also be available on the website of the SEC at http://www.sec.gov .

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, anxiety, and post-traumatic stress disorder (PTSD).

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012 .

SOURCE Neuralstem, Inc.

Deanne Eagle - Media Relations, +1-917-837-5866, or Susan Roush - Investor Relations +1-818-222-8330

Palisade Bio, Inc. (PALI) Stock Research Links

PALI Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sportradar and DATA.BET: Expanding Esports Odds Offering

A Shift in the Esports Betting Landscape Well, it looks like we’ve hit another significant milestone in the esports betting universe. Sportradar, the sports tech giant known for pushing boundaries, has forged an intriguing alliance with DATA.BET, a sportsbook hotshot hailing from Cyprus. We're talking about a deal that’s set to shake up the esports betting scene with...

AI Deception Challenges the Confidence of Fraud Defenses

Fraud Week Spotlights AI Deception Alright, here's the rub: we're in Fraud Week 2026, and boy, is AI shaking the foundations of yesterday's fraud defenses! With all this AI talk, you would expect systems to be near invincible by now. But reality? A different beast altogether. AI has this knack of tripling up the complexity while pretending to solve it, making traditional...

Choosing Dance Styles: Tips from Expert Instructors

Navigating the Dance Style Maze Picking a dance style is no joke, especially when every option seems to spin its own tale. It ain't just about twirling to your favorite rhythm. There's a whole spectrum of styles, from graceful ballet to punchy hip-hop, each with its ticklish quirks and temptations. Sandy Young and Jenna Engen, dance experts from Young Dance Academy Inc....

Dyania, NVIDIA Team Up: AI Transforming Patient Care

Revving up efficiency in healthcare usually sounds like pie-in-the-sky talk, but every now and again, an innovation comes along that really stirs the pot. Enter Dyania Health's Synapsis AI, a clinical reasoning AI, teaming with NVIDIA's robust computing infrastructure. They're setting out to make sense of massive amounts of patient data, securely tucked behind a...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Aluminum Fluoride Market to Hit $3.3B by 2031

By Ryan Hughes Updated Nov 13, 2026 Category News Views 124

Eye on the Aluminum Fluoride Surge Cracking open the numbers, the aluminum fluoride market is projected to swell from $2.48 billion in 2026 to a hefty $3.30 billion by 2031, trucking along at a CAGR of 5.9%. That's no small potatoes in the world of industrial materials. Scratch the surface, and you’ll see what's fueling this climb—think of it as a bellwether for...

Classys Rides Revenue Surge, Eyes China Growth

By Caleb Price Updated Nov 13, 2026 Category News Views 108

Strong Numbers, But There's More to Unpack Nine months into 2026, Classys Inc. ain't exactly putting up shabby numbers. They've rolled in with KRW 275.7 billion like it was a stroll in the park, marking a sturdy 13% jump from last year. Yet, with all this, their operating profit has taken a 9.4% spill. It's a mixed bag, folks, and Classys is gearing up for a massive...

Timken Maintains Robust Dividend Streak in 2026

Timken Keeps Dividend Train Rolling You want to talk consistency? Timken Company just declared its quarterly dividend like clockwork. As a stockholder, that might just be your morning coffee fix before anything else. Notably, Timken's been on the NYSE since 1922, having cranked out 418 consecutive dividend payouts. That's like your grandpa never missing a Sunday golf...

vVARDIS Readies for Big Day on NYSE—IPO Set to Shine

vVARDIS Stepping into the Spotlight of the NYSE Alright, folks, here's one that could make some waves. vVARDIS is gearing up for its NYSE debut, trading under the ticker VVVV. They're no small fry talking about 9.72 million shares priced at 18 bucks a pop. This isn't just any run-of-the-mill company; they claim to have the first peptide-containing formulation for early...

Duke Energy's Cooling Tips Amid Florida Cold Front

Weather Whiplash in Florida Prompts Energy Tips Florida's residents are in for a gust of chilly air as a cold front sweeps across the state, sending temperatures plummeting from the balmy 80s to brisk 30s and 40s in northern pockets. Central Florida ain't missing out on the chill either, expecting to dip a good dozen degrees below its usual seasonal warmth. Heads up,...